A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma

This study develops personalized treatment plans for patients with cutaneous T-cell lymphoma (CTCL) — a cancer affecting immune cells in the skin — based on the specific genetic subtype of their cancer to improve outcomes beyond standard skin-targeted treatments. **You may be eligible if...** - You have been diagnosed with CTCL that has not responded well to topical (skin) treatments like corticosteroids, nitrogen mustard, or light therapy (phototherapy) - You are between 18 and 75 years old - Your expected survival is more than 3 months **You may NOT be eligible if...** - You received anti-cancer therapy (other than skin-targeted treatment) in the past month - You have two or more types of primary cutaneous T-cell lymphoma at the same time - You have another active cancer currently being treated - You have epilepsy, autoimmune diseases, liver failure, or significant kidney disease - You have serious uncontrolled infections or heart/lung conditions - You are pregnant, planning pregnancy, or breastfeeding Talk to your doctor to see if this trial is right for you.